JW Pharmaceutical’s Gout Drug Candidate Outperforms Febuxostat in Phase 3 Trial

From the publisher

JW Pharmaceutical has reported positive results from a multinational Phase 3 trial of its gout drug candidate epaminurad (code name URC102), with the 6mg dose demonstrating statistically superior efficacy in lowering blood uric acid levels compared with febuxostat, a widely used standard treatment.T

The source's own excerpt, unedited